Hayashi S, Matsubara T, Maeda T, Fukuda K, Funahashi K, Hashimoto M
Sci Rep. 2022; 12(1):17524.
PMID: 36266430
PMC: 9585052.
DOI: 10.1038/s41598-022-22152-w.
Huang A, Shu L, Chen Z, Zhang C
PLoS One. 2022; 17(7):e0272357.
PMID: 35905126
PMC: 9337630.
DOI: 10.1371/journal.pone.0272357.
Faramarzi F, Zafari P, Alimohammadi M, Golpour M, Ghaffari S, Rafiei A
Inflammation. 2022; 45(6):2433-2448.
PMID: 35713788
DOI: 10.1007/s10753-022-01703-3.
Hayashi S, Matsubara T, Fukuda K, Funahashi K, Hashimoto M, Maeda T
Sci Rep. 2020; 10(1):16645.
PMID: 33024253
PMC: 7538428.
DOI: 10.1038/s41598-020-73968-3.
Kaczynski T, Wronski J, Gluszko P, Kryczka T, Miskiewicz A, Gorski B
Cent Eur J Immunol. 2020; 44(3):269-276.
PMID: 31933536
PMC: 6953371.
DOI: 10.5114/ceji.2019.89601.
Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
Biggioggero M, Crotti C, Becciolini A, Favalli E
Drug Des Devel Ther. 2018; 13:57-70.
PMID: 30587928
PMC: 6304084.
DOI: 10.2147/DDDT.S150580.
Sarilumab: patient-reported outcomes in rheumatoid arthritis.
Crotti C, Biggioggero M, Becciolini A, Favalli E
Patient Relat Outcome Meas. 2018; 9:275-284.
PMID: 30154675
PMC: 6108331.
DOI: 10.2147/PROM.S147286.
Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.
Suzuki K, Yoshida K, Ueha T, Kaneshiro K, Nakai A, Hashimoto N
Arthritis Res Ther. 2018; 20(1):55.
PMID: 29566767
PMC: 5863822.
DOI: 10.1186/s13075-018-1552-9.
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo M, Biggioggero M, Crotti C, Becciolini A, Favalli E
Drug Des Devel Ther. 2017; 11:1593-1603.
PMID: 28579757
PMC: 5447699.
DOI: 10.2147/DDDT.S100302.
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.
Ruiz-Padilla A, Gamez-Nava J, Saldana-Cruz A, Murillo-Vazquez J, Vazquez-Villegas M, Zavaleta-Muniz S
Biomed Res Int. 2016; 2016:4193538.
PMID: 27738630
PMC: 5050320.
DOI: 10.1155/2016/4193538.
Chlorogenic acid induces apoptosis to inhibit inflammatory proliferation of IL-6-induced fibroblast-like synoviocytes through modulating the activation of JAK/STAT and NF-κB signaling pathways.
Lou L, Zhou J, Liu Y, Wei Y, Zhao J, Deng J
Exp Ther Med. 2016; 11(5):2054-2060.
PMID: 27168850
PMC: 4840502.
DOI: 10.3892/etm.2016.3136.
Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.
Jiang X, Zhuang Y, Xu Z, Wang W, Zhou H
AAPS J. 2016; 18(3):767-76.
PMID: 26961818
PMC: 5256608.
DOI: 10.1208/s12248-016-9890-5.
Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review.
Alves C, Farrell E, Vis M, Colin E, Lubberts E
Clin Rev Allergy Immunol. 2015; 51(1):27-47.
PMID: 26634933
PMC: 4961736.
DOI: 10.1007/s12016-015-8522-7.
Interleukin 6 and rheumatoid arthritis.
Yoshida Y, Tanaka T
Biomed Res Int. 2014; 2014:698313.
PMID: 24524085
PMC: 3913495.
DOI: 10.1155/2014/698313.
IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro.
Kaneshiro S, Ebina K, Shi K, Higuchi C, Hirao M, Okamoto M
J Bone Miner Metab. 2013; 32(4):378-92.
PMID: 24122251
DOI: 10.1007/s00774-013-0514-1.
Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review.
Al-Shakarchi I, Gullick N, Scott D
Patient Prefer Adherence. 2013; 7:653-66.
PMID: 23869169
PMC: 3706382.
DOI: 10.2147/PPA.S41433.
Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.
Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D
BMC Infect Dis. 2013; 13:203.
PMID: 23641933
PMC: 3655873.
DOI: 10.1186/1471-2334-13-203.
-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.
Jancic I, Arsenovic-Ranin N, Sefik-Bukilica M, Zivojinovic S, Damjanov N, Spasovski V
Rheumatol Int. 2012; 33(6):1481-6.
PMID: 23233117
DOI: 10.1007/s00296-012-2586-y.
Adenosine A2A receptor and TNF-α regulate the circadian machinery of the human monocytic THP-1 cells.
Perez-Aso M, Feig J, Mediero A, Aranzazu M, Cronstein B
Inflammation. 2012; 36(1):152-62.
PMID: 22923002
PMC: 3553238.
DOI: 10.1007/s10753-012-9530-x.
The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines.
Gibbs J, Blaikley J, Beesley S, Matthews L, Simpson K, Boyce S
Proc Natl Acad Sci U S A. 2011; 109(2):582-7.
PMID: 22184247
PMC: 3258648.
DOI: 10.1073/pnas.1106750109.